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Abstract
The atypical antipsychotic Abilify is the second most popular treatment for schizophrenia and
other related disorders. Its popularity and wide use is due to its unique pharmacological profile,
working differently at dopamine and serotonin receptors compared to other antipsychotics.
Schizophrenia is an infamous mental dysfunction involving cognitive impairment, positive
symptoms, and negative symptoms. The current study investigated Abilify’s effect in a dosedependent manner on memory, coordination and stereotypic movement. The sample consisted of
15 male and 15 female CD-1 mice. Memory was tested in a cognitive maze, the Rota-Rod series
8 model measured coordination, and the Coulbourn Tru-Scan Activity Box recorded stereotypic
movements. Abilify did not significantly affect memory, it inhibited coordination at all doses for
female mice and at the highest dose for male mice, and it induced stereotypic movements at the
lowest dose and inhibited such movements at the highest dose for male and female mice.
Keywords: Abilify, aripiprazole, antipsychotic, schizophrenia, dopamine, serotonin, memory,
cognitive maze, coordination, Rota-Rod, stereotypy, Tru-Scan, CD-1 mice
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The Effect of Abilify on Memory, Coordination, and Stereotypy in CD-1 Mice
Abilify is the second most popular pharmacological treatment for schizophrenia and
psychosis-related disorders, yet there is scarce scientific literature on patients’ premorbid history
prior to being placed on this highly influential drug. Additionally, there is very little literature
pertaining to long-term use of Abilify in the clinical population; however, there is an abundance
of novel information on the behavioral, molecular, and social aspects of schizophrenia. This
thesis will explain the psychopathology of schizophrenia and the relevance of Abilify as a
psychotropic medication and explain many of the side effects of various doses of this
medication, as well as investigate its effects on memory, coordination, and stereotypic
movement.
One of the most infamous and well-known mental dysfunctions, schizophrenia is both as
fascinating a disorder as it is misunderstood. Schizophrenia involves three key dimensions:
cognitive impairment, positive symptoms, and negative symptoms (Rajagopal, Massey, Huang,
Oyamada & Meltzer, 2014). Positive symptoms include hallucinations (false perceptions),
delusions (false beliefs), and deranged thoughts and behaviors, while negative symptoms include
loss of motivation, affective flattening, restricted emotional experience, reduced hedonic
capacity, and disorganized speech (saying things that do not make sense) (Topolov & Getova,
2016). It is not unusual for schizophrenic patients to suffer from abnormal perceptions
(eyetracking problems, slight movement disturbances), strange inferential judgments that lead to
extraordinary beliefs and delusions, restricted emotions, and widespread cognitive problems
(Topolov & Getova, 2016).
Schizophrenia is a devastating disorder for both patients and families and the second
leading cause of disease burden. The three phases of most schizophrenic patients include the
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prodromal phase, the active phase, and the residual phase. The prodromal phase is more
important to this thesis since it includes peculiar behaviors, such as pacing, movement
disturbances and restlessness. Although there are 3 key symptoms, no single symptom or specific
set of symptoms is characteristic of all schizophrenic patients. Since there are many different
clinical manifestations and levels of severity, The Diagnostic and Statistical Manual of Mental
Disorders now lists Schizophrenia under Spectrum Psychotic Disorders. This heading now
includes schizophrenia, schizoaffective disorder, delusional disorder, brief psychotic disorder,
and psychotic mania, all of which might be alleviated or attenuated by the drug Abilify.
Although there is a commonality involving a break in reality with all of these disorders, the three
dimensions are mostly uncorrelated and consequently respond differently to antipsychotic
treatment (Rajagopal et al., 2014). Specifically, cognitive impairment prevents patients from
learning and memorizing the skills that are necessary for social relationships, accounting for
more poor functional outcomes such as occupational functioning, social attainment, and
independent living, than the other two dimensions, and in schizophrenic patients this might
become visible before other neurological impairments, affecting working memory, attention, and
learning (Topolov & Getova, 2016). Typically, cognitive impairments present first, developing
completely before the onset of psychotic episodes in schizophrenic patients, but not in
schizoaffective, schizophreniform, or manic psychotic patients (Topolov & Getova, 2016).
Therefore, it would be beneficial to understand the effects of Abilify on memory prior to
administration as well as future long-term effects on cognition.
The psychotic episodes involve breaks in reality and includes disconnected ideas (using
words in peculiar ways, loose associations, otherwise known as derailment (i.e., switching topics
too abruptly), and perseveration (e.g., persistently repeating the same word or phrase over and
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over). This can even develop into what is now known as thoughtblocking, where the patient’s
train of thought is interrupted before an idea has been completed. Disorganization is another
commonly seen bizarre behavior which may include a catatonic-like psychosis, which involves
immobility and marked muscular rigidity, or wild excitement and overactivity. This altered state
of responsiveness is of primary importance to this thesis, since most antipsychotic medications
will further sedate or suppress movement.
While systematic tests for schizophrenia were developed by the 1940s, most of what is
known regarding cognitive impairment in psychotic related illnesses came from targeted research
that began in the 1980s (Topolov & Getova, 2016). Schizophrenic patients have been found to
perform worse than control patients in all twelve neurocognitive domains: general intellectual
ability, verbal memory, nonverbal memory, recognition, executive functions, motor skills,
working memory, language, attention, and processing speed (Topolov & Getova, 2016). In
particular, schizophrenic patients’ ability to work fulltime is impacted by cognitive functioning,
even prior to drug administration. Readministration of IQ tests to individuals who developed
schizophrenia showed little change, implying that most of the intellectual decline occurred prior
to the onset of the first psychosis (Topolov & Getova, 2016). For schizophrenics, the severity of
the cognitive impairment in their first-episode is equivalent to the cognitive impairment in
individuals with chronically established schizophrenia, highlighting neurocognitive deficits as
one of the more stable traits of schizophrenia (Topolov & Getova, 2016). Moreover, genetic
relatives of schizophrenic patients have shown attenuated cognitive impairment, meaning that
neurocognitive domains may be genetic markers for schizophrenia (Topolov & Getova, 2016).
The success of various pharmacological therapies in psychotic patients has led to the
proposal of 3 models: the dopamine hypothesis, the glutamate hypothesis, and the serotonin
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hypothesis. Each model attempts to explain both the neuroreceptor targets for antipsychotics and
how various neuroreceptors influence specific symptoms and side effects (Topolov & Getova,
2016). Among the models, the dopamine hypothesis is the most studied. It states that
schizophrenia is due to an abundance of dopamine in the brain. More precesily, it suggests that
hyperactivity of the mesolimbic dopaminergic pathway mediates symptoms of psychosis, while
the negative and cognitive symptoms are mediated by separate mesocorted hypoactive
dopaminergic pathways (Topolov & Getova, 2016). However, we now have greater technology
showing us that this hypothesis does not tell the whole story. There are other interactions as
previously stated with GABA and glutamate, but also with serotonin pathways (explaining most
of the negative symptoms). COMT (located on chromosome 22) has also been looked at. This is
a specific gene that is involved in breaking down the neurotransmitter dopamine, which may
contribute to the movement disorders that are linked to the dysfunction as well as the
medications to the dysfunction. Extrapyramidal symptoms (EPS) are motor side effects due to
long standing treatments with antipsychotics; however, literature is now showing that some of
the tremors, restlessness, and muscular rigidity are due to the imbalance of dopamine in the brain
and not due to medications alone. Although the glutamate hypothesis states that schizophrenia is
the result of hypo-activity on NMDA receptors, these receptors rarely modulate memory or
movement (Leite, Guimaraes, & Moreira, 2008). However, the glutamate and serotonin
hypothesis are less important with this thesis since Abilify primarily affects the dopamine
system, involved in active symptoms, cognition, and movement.
While patients with schizophrenia demonstrate deficits across many cognitive domains,
the underlying cognitive and neural mechanisms of the disorder are unclear. For instance, the
striatal dopamine system is involved in signaling prediction errors and integrating them over
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trials, while the prefrontal cortex is involved in using working memory to test hypotheses and
represent values of prospective outcomes to guide choice (Collins, Brown, Gold, Waltz & Frank,
2014). The contributions of two separable cognitive processes, working memory (WM) and
reinforcement learning (RL), are confounded by most learning paradigms, leading Collins et al.
to develop a model to separate WM from RL. While patients with schizophrenia do show failure
in RL, Collins et al. found that learning impairment in schizophrenic patients was due to deficits
in WM rather than deficits in RL (2014). More precisely, they found that patients with
schizophrenia had reduced WM capacity and faster WM decay, while RL rates were normal.
This suggests that the inability of patients with schizophrenia to learn from outcomes stems from
WM deficits rather than RL deficits. WM contributes to other aspects of cognition, including
fluid reasoning and language comprehension, meaning that WM impairments could contribute to
many of the cognitive deficits seen in schizophrenia, and thus would be detrimental to put them
on a medication that might increase their memory loss. While they hypothesized that negative
symptom severity was related to WM parameters, no association was found, perhaps because the
task they used more closely related to WM processes involving the lateral prefrontal cortex,
while negative symptoms are hypothesized to be attributed to the limbic portions of the
prefrontal cortex, such as the orbitofrontal cortex (Collins et al., 2014).
Neuroanatomical studies of the dopamine system are widely published; however, there
are very little, if no studies, identifying the effect on neural communication, both pre- and postmedication. Interdependence of firing rates in dorsolateral prefrontal cortex and parietal cortex is
vital for WM performance (Deserno, Sterzer, Wustenberg, Heinz, & Schlagenhauf, 2012). The
dysconnectivity hypothesis of schizophrenia focuses on abnormal synaptic plasticity. WMdependent modulation of effective connectivity from dorsal-lateral prefrontal cortex (dlPFC) to
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parietal cortex was shows to be reduced in schizophrenic patients, showing that this
dysconnectivity could be a specific mechanism underlying cognitive deficits seen in
schizophrenia (Deserno et al., 2012).
Typical antipsychotics, such as Thorazine and mellaril, can reduce the activity of
hyperactive dopaminergic pathways by inhibiting dopamine transmission, thus reducing positive
symptoms that are related to hallucinations and delusions (Topolov & Getova, 2016). More
precisely, typical antipsychotics work as full antagonists at dopamine D2 receptors (Topolov &
Getova, 2016). However, the dopamine inhibition causes unwanted side motor effects, but less
dry mouth and memory disturbances. However, some psychotropic medications (Thioridazine,
Haldol, and other piperadines) diminish levels of dopamine in pathways where dopamine excess
was not a problem, such as the mesocortical, nigrostriatal, and tuberoinfundibular pathways, and
thus induce extrapyramidal side effects (EPS) and possibly cause cognitive impairment (Topolov
& Getova, 2016). Negative symptoms and cognitive symptoms often worsen on long-term
psychotropic medications, since these behaviors are not mediated through typical dopamine
receptor subtypes, but rather incorporate other systems, such as the serotonin and norepinephrine
systems (Topolov & Getova, 2016).
Consequently, D2 receptor antagonists are known to induce catalepsy and cause increased
dopamine metabolism in the striatum, where their effects contribute to extrapyramidal motor side
effects (EPMS), and in the limbic system, where their effects contribute to antipsychotic activity
(Kirschbaum, Hiemke, & Schmitt, 2009). To provide an example of EPMS, D2 receptors have
been shown to play a role in central components of locomotion, such as time spent in motion,
horizontal distance traveled, and initiating movement, meaning that D2 receptor antagonists
could inhibit locomotion (Kirschbaum et al., 2009). As demonstrated by Sanberg’s 1980 study, a
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typical antipsychotic such as haloperidol would induce catalepsy by blockade of postsynaptic
striatal dopamine D2 receptors (qtd. in Kirschbaum et al., 2009). Atypical antipsychotics, such
as clozapine, Risperdal, and Abilify, work on serotonin receptors in addition to dopamine
receptors, and are known for inducing less EPS than typical antipsychotics (Topolov & Getova,
2016). Additionally, atypical antipsychotics do not increase prolactin secretion and may improve
cognitive impairment (Topolov & Getova, 2016). It has been shown that the preferable EPS
effects are attributed to serotonin 5-HT2A,C receptor antagonism and/or 5-HT1A partial agonism,
while the cognitive enhancement is attributed to 5-HT6 and 5-HT7 receptor antagonism (Topolov
& Getova, 2016). Moreover, the pathophysiologic mechanism of schizophrenia is thought to be
based on too much dopamine activity in some regions and too little dopamine activity in other
regions, which has led to research focusing on developing D2 partial agonists. These could work
as antagonists in areas with too much dopamine activity, and work as agonists in areas with low
dopamine activity (Topolov & Getova, 2016). Thus, D2 partial agonists could reduce positive
symptoms while not inducing EPS or elevated prolactin levels.
Aripiprazole (brand name Abilify) is a psychotropic drug commonly used to treat many
forms of psychosis. It is available as tablets, orally disintegrated tablets, oral solution, and
injection (Topolov & Getova, 2016). Its chemical formula is 7-[4-[4-(2,3-dichlorophenyl)-1piperazinyl]butoxy]-3,4-dihydrocarbostyril, while the empirical formula is C23H27Cl2N3O2, and
its molecular weight is 448.39 (Topolov & Getova, 2016). After oral administration, peak plasma
concentrations occur after 5 to 7 hours, and the absolute oral bioavailability is 87% (Topolov &
Getova, 2016). When administered intramuscularly, the peak time is between 1 and 3 hours and
the absolute bioavailability is 100% (Topolov & Getova, 2016). There are 3 primary
biotransformation pathways that metabolize aripiprazole: dehydrogenation, hydroxylation, and
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N-dealkylation (Topolov & Getova, 2016). The elimination half-life is considered to fall within
75 hours to 146 hours. The active metabolite, dehydro-aripiprazole, is present for an additional
146 hours. The cytochrome P 450 enzymes CYP3A4 and CYP2D6 are responsible for
aripiprazole metabolism.
Despite being an atypical antipsychotic, aripiprazole’s mechanism of action differs from
other atypical antipsychotics such as clozapine, olanzapine, and risperidone. Where other
antipsychotics act as antagonists at D2 receptors, aripiprazole acts as a partial agonist at D2
receptors and at 5-HT1A receptors (Topolov & Getova, 2016). Aripiprazole’s profile leads to
antagonistic activity in areas with dopaminergic hyperactivity and agonist activity in areas with
dopaminergic hypoactivity, decreasing the risk of EPS and some catalepsy compared to some
older antipsychotics and other new atypical antipsychotics (Kirschbaum et al., 2009). Two
animal models for predicting EPS in humans are inducing catalepsy in rodents that reflects the
substantial decrease in dopamine signaling at postsynaptic striatal D2 receptors and the Rota-Rod
test, which tests coordinated motor skills. In their 2009 study, Kirschbaum et al. investigated the
effects of aripiprazole and other antipsychotics on motor impairment using the catalepsy and
Rota-Rod tests. Three doses of aripiprazole were administered: 1mg/kg, which showed no motor
impairment, and 5mg/kg and 10mg/kg, which caused significant motor impairments and also
induced catalepsy (Kirschbaum et al., 2009). Aripiprazole induced less motor impairment than
haloperidol or risperidone, as these drugs caused impairments even at low doses (Kirschbaum et
al., 2009). Also, 5-HT1A receptor activation increases dopamine release in a regionally selective
manner in the prefrontal cortex, suggesting alleviation of the proposed deficiency in
dopaminergic neurotransmission in this brain region in schizophrenics (Bardin, Kleven, BarretGrevoz, Depoortere, & Newman-Tancredi, 2005). Activation of this receptor has also been
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shown to improve negative symptoms as well as cognitive symptoms (Bardin et al., 2005). Like
other antipsychotics, aripiprazole works as an antagonist at 5-HT2A receptors and the 5-HT7
receptor, and it also works as a partial agonist at the 5-HT2C receptor (Topolov & Getova, 2016).
Aripiprazole has been shown to enhance short-term memory and long-term memory on the
inhibitory avoidance task (Nascimento et al., 2011)
Aripiprazole dampens the action of dopamine and serotonin in the brain, lowering
abnormal levels of excitement, and inhibiting the more extreme moods associated with psychotic
disorders. It is used as acute and maintenance treatment for manic or mixed episodes in bipolar I
disorder as monotherapy, or as an adjunct to lithium or valproate. It is also used as an adjunct to
antidepressants for major depressive disorder. While it is also used to treat autistic disorder, it
has been associated with irritability.
Despite aripiprazole’s preferable profile, it does not come without risks. It should not be
used by elderly with dementia-related psychosis or those with a history of
leukopenia/neutropenia. The drug presents an increased risk of death or cerebrovascular events,
hypotension, aspiration pneumonia, seizures, and diabetes. Also, patients receiving aripiprazole
need to be monitored for hyperglycemia, dyslipidemia, and weight gain. There is also an
increased risk of suicidal thoughts and behavior in children, adolescents, and young adults. Other
adverse reactions include drowsiness, headache, anxiety, insomnia, constipation, nausea,
vomiting, somnolence, fatigue, sedation, dizziness, restlessness, akathisia, blurred vision, tremor,
pyrexia, salivary hypersecretion, EPS, neuroleptic malignant syndrome, and tardive dyskinesia.
One challenge in antipsychotic research is that schizophrenia cannot be fully mimicked in
healthy volunteers or laboratory animals. As such, psychotomimetics (drugs that can mimic some
symptoms) are used to test the efficacy of antipsychotic drugs to prevent the psychotomimetic
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drugs’ effects. Amphetamine enhances the release of monoamines, thus increasing the levels of
dopamine in meso-limbico-cortical and meso-striatal pathways, and may cause delusions and
hallucinations in humans, mimicking positive symptoms of schizophrenia (Leite et al., 2008).
Phencyclide, ketamine, and MK-801 act as antagonists at the glutamate NMDA receptor,
mimicking some positive and negative symptoms such as social isolation and cognitive deficits
(Leite et al., 2008). Recall that the glutamate hypothesis states that schizophrenia is the result of
hypo-activity on NMDA receptors, thus explaining why these particular psychomimetics may be
useful (Leite et al., 2008). In rodents, psychotomimetics induce behavioral changes such as
motor hyperactivity, reduced social interaction, and impairment in the pre-pulse inhibition of the
startle reflex (Leite et al., 2008). Aripiprazole has been shown to inhibit the stereotyped behavior
and the impaired pre-pulse inhibition induced by apomorphine (dopamine agonist) in rats (Leite
et al., 2008). While aripiprazole did not inhibit spontaneous locomotion, significantly less
movement was observed (Leite et al., 2008). The drug inhibited amphetamine-induced
locomotion and cocaine-induced motor hyperactivity, both drugs that enhance dopaminemediated neurotransmission. Also, the highest dose of aripiprazole inhibited hyperlocomotion
induced by MK-801 while the lowest dose of aripiprazole enhanced it. This study also showed
that the highest dose of aripiprazole produced catalepsy, but to a lower extent than haloperidol
(Leite et al., 2008). Antipsychotics’ liability to induce catalepsy correlates well with D2 receptor
antagonism, whereas aripiprazole has been shown to not induce significant motor impairments,
even in doses that induce 95% of receptor occupation. This is most likely due to its partial
agonism at these receptors (Leite et al., 2008). Additionally, aripiprazole induces less EPS at
higher doses than other antipsychotics, demonstrating its lack of aversive side effects (Leite et
al., 2008).
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Since previously mentioned studies show that working memory and retention are
unstable in schizophrenic patients, it would be beneficial to know whether or not Abilify affects
memory in normal mice, let alone schizophrenic animal models. Schizophrenic patients show
deficits in spatial WM tasks by having significantly lower recognition rates for previously seen
objects. They differ from “normal controls in regional cerebral blood flow changes in the
pulvinar region of the right thalamus and the right or left prefrontal cortex during the recognition
of new and previously seen objects” (Rajagopal et al., 2014). The hippocampus, the prefrontal
cortex, the nucleus accumbens, and the dorsal striatum are implicated in the pathobiology of
schizophrenia (Rajagopal et al., 2014). These neural systems require “closely modulated
glutamatergic, GABAergic, cholinergic, dopaminergic, serotonergic, and nitric oxide-dependent
neurotransmitters and growth factors for their action to achieve one-trial memory formation and
retention for a limited period of time” (Rajagopal et al., 2014, p. 3).
The hypotheses of this thesis are that Abilify will significantly increase memory, that the
lowest dose will induce stereotypy while the highest dose will inhibit stereotypy, and that the
highest dose will inhibit coordination while the other doses will have little or no effect.
Methods
Subjects
Fifteen adult male (42-58g) and 15 adult female CD-1 mice (33-44g) were purchased
from Charles River Laboratories Inc., (Portage MI) and housed in the Long Island University
Animal Vivarium. Animals were housed in same sex groups (8-10 adult mice per cage) in a
temperature-controlled room maintained on a 12-h light /12-h dark cycle, and food and water
were available to the mice ad libitum. Mice were divided into 2 groups for both genders, (n =
10/experimental group and n=5/control group). Control group subjects were tested once while
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experimental group subjects were tested at three doses, and studies were carried out in
accordance with The National Institutes of Health Guidelines and regulations specified by the
LIU-Post Animal Care & Use Committee.
Drug
Abilify (Aripiprazole) was purchased from Fisher Scientific (Union City, CA) and was
dissolved in 0.9% saline and Tween 80. The drug was tested during their peak time of effect
(Abilify’s peak time of effect is 30 minutes). A vehicle of 0.9% saline solution was injected as a
control in 5 males and 5 female mice and used as vehicle comparisons. All intraperitoneal
injections were administered via 1 milliliter (ml) syringes with 28 gauge needles infused with
either saline or the drug solution.
Apparatus
The Cognitive Maze (see Appendix A) consists of a 30cm x 30cm wooden box with a
removable Plexiglas top. Spatial memory was tested within this box using a stopwatch
(Sportline) and an error counter (Sportline) (a picture of the maze and the other lab machinery
used in the study can be seen in the appendix).
The Rota-Rod series 8 model (see Appendix B) from the IITC-755 Life Sciences
Company (Victory Blvd, Woodland Hills, CA 91367) consists of five elevated rods (diameter
1.25” each, which is optimal for mice to grip onto and run on), and 5 individual lanes enclosed
via Plexiglas screens. Clear Plexi-Glass front panels are supplied for viewing during test. Test
parameters are entered via the front panel keyboard. All test results are displayed on the front
panel display and also sent out the rear panel printer port. The test ending results for each
position are rpm’s (revolutions per minute), test time, and distance traveled in meters. The user
selects from 1 to 5 lanes at a time of testing to be included in the test. The Roto-Rod is designed
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to enable the operator a more precise reading of equilibrium thresholds for coordination and
endurance. This digitally controlled unit has a high degree of repeatability but all mice are
acclimated on the machine prior to any baselines or testing. Specifically, mice are placed on
textured drums to avoid slipping. Textured drums, which act like round-treadmills begin to turn
slowly and the animal begins to walk on it. When the animal drops off of the textured drum (18.5
cm), it activates a sensing platform below. Elapsed time, distance, and rpm’s can then be
recorded.
The Coulbourn Tru-Scan Activity Box (see Appendix C) consists of two plexiglas, boxlike arenas containing photobeam sensors (2mm part) along the ventral surface of the arena
(E63-12 model). Specifically, the Activity Boxes can be used to measure and record various
horizontal floor movements, stereotypical motions, locomotor activities, as well as other
behaviors such as jumping and resting through floor and wall sensors. Sensor rings: Tru-Scan’s
photobeam sensor rings are separate from the station’s processor. There is only one type of
sensor ring. It senses in two dimensions. The same ring is used for FP (floor plane) sensing. The
connector into which you plug the ring determines its recording function. The system logs
coordinates instead of just a “yes or no.” Tru-Scan’s precision is 32 x 32cm, twice the cage’s
beam resolution; 0.5 inch (1.27 cm) for the beam spacing of the large cage and 0.3 inch (.76 cm)
for spacing of the small cage. This is accomplished by calculating the spread between the lowest
and the highest beam blocked and defining the coordinate as one half the distance between the
two. To get readings, mice need to be placed on the gray, square plastic floor of the activity box
arena which allows the experimenter to view the mice during the tests. The protocol set up for
the activity boxes for each mouse was 10 minutes long. The following operational definitions
were used for the activity variables. Total movements (TM) were defined for each movement as
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a series of successive coordinate changes with no rest for at least 1 sample interval. Latency to
First Movement (LFM) is defined as datum measuring the latency from run start to the first
coordinate change and then to the 5th, 10th, 20th, 50th, and 100th unit (inches or centimeters) of
distance traveled. Rest Time (RT) is operationally defined as the total session time less Total
Movement Time (TMT) is defined as the sum total of elapsed time of all movements in the floor
plane). Stereotypy (STPY) or stereotypical movements are measured as repetitive behaviors
which do not contribute to large location changes progressively further from the starting point
(e.g., grooming behavior, shaking, or a seizure etc.). Stereotypy Moves are defined as the total
number of coordinate changes less than plus or minus 0.999 beam spaces in each floor plane (X
and Y) dimension and back to the original point that do not exceed 2 seconds apart. Stereotypy
Episodes are defined as the total number of episodes of stereotypic moves. Three such
movements must be made before a stereotypy episode starts, and when it does, the qualifying 3
movements are included in the total number of moves. When the subject moves outside of the
region of qualified coordinates, or fails to move within them for 2 seconds, the episode breaks
and its current position becomes the new starting point.
Measurements of body weights were taken on a scale from Salter Housewares
(Tonbridge, Kent) prior to and after the behavioral testing.
Procedure
The study was conducted in a scientific laboratory at a college campus. Baselines were
taken on all apparati for all mice prior to the start of the study. Two mice at a time were injected
with the desired dose (0.1mg/kg, 5mg/kg, 20mg/kg) with an injection volume of 0.2cc’s.
Twenty-seven minutes after the mice received their dose (which was the peak time of the drug’s
action), the mice were evaluated (2x each) for distance traveled (how long the mice ran before
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they fell off the rod), rotations per minute (rpm), and time were recorded both times on the RotoRod. Immediately thereafter, each mouse was separately run through a maze that contained a
food pellet at the end (this was recorded as elapsed time-to-goal). Time was recorded as the
amount of seconds it took for a mouse to go from the start of the maze to the food pellets with 3
minutes as the cut-off time. Maze errors and elapsed time were recorded using a stopwatch and
an error counter. An error was recorded every time a mouse went in a direction that did not lead
to the pellets. The mice were then put in the Tru Scan Activity Arenas and activity was recorded.
Overall activity was recorded using the Tru Scan for 10 minutes. 10 minutes ensured that the
mice would be in the activity box during the peak time effect of the antipsychotic medication.
Data Analysis
Statistical significance (p < .05) was assessed for analgesia using GraphPad Prism
Graphing and Statistical program using Student's t test when comparing 2 means or a 1-way
Analysis of Variance (ANOVA) was used for the comparison of 3 or more means. This was
followed by Tukey's Post-hoc Test to identify where (which gps) significance was located (San
Diego, CA, USA).
Results
One-way ANOVA tests were conducted to test for significant effects. If significant
effects were found, post-hoc comparison’s using Tukey’s post-hoc tests were done.
In a dose-dependent manner, Abilify (0.1 – 20 mg/kg) significantly increased latency-togoal for female mice (n = 6-10) when challenged in a classic maze, F(2, 22) = 5.50, p < 0.05 (see
Figure 1b). Tukey’s post-hoc test showed that female mice spent significantly longer time to
complete the maze at 20mg/kg compared to 0.1mg/kg and 5mg/kg. Abilify (0.1 – 20 mg/kg) did
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not significantly affect latency to goals for male mice (n = 6-10) when challenged in a classic
maze, F(2, 22) = 0.77, p > 0.05 (see Figure 1a).
Abilify (0.1 – 20 mg/kg) did not significantly affect errors in memory for male mice (n =
6-10) when challenged in a classic maze, F(2, 22) = 0.75, p > 0.05 (see Figure 2a). Abilify (0.1 –
20 mg/kg) did not significantly affect errors in memory when female mice (n = 6-10) were
challenged in a classic maze, F(2, 22) = 0.58, p > 0.05 (see Figure 2b).
Catalepsy is a condition characterized by lack of response to external stimuli and by
muscle rigidity, so that the limbs remain where they are positioned. Catalepsy is a symptom of
certain nervous disorders such as Parkinson’s disease and epilepsy, but is also a characteristic
feature of catatonic schizophrenia. The mice in this study were all examined prior to testing for
any signs of catalepsy, and no signs were found. Once drug administration was initiated, if any
signs of catalepsy were seen, it was assumed that this was a result of the drug, not any prior CNS
dysfunction in the mice. At 20mg, some female mice were cataleptic, eliciting less movement as
shown by a decrease from the lowest dose. Abilify (0.1 – 20 mg/kg) did not significantly affect
the total distance that male mice (n = 6-10) traveled on the Rota-Rod, F(3, 110) = 1.24, p > 0.05
(see Figure 3a). However, in a dose-dependent manner, Abilify (0.1 – 20 mg/kg) significantly
affected the total distance that female mice (n = 6-10) traveled on the Rota-Rod, F(3, 104) =
8.83, p < 0.001 (see Figure 3b). Tukey’s post-hoc test verified that all three doses significantly
impacted total distance traveled in females, as compared to their baseline times.
Abilify (0.1 – 20 mg/kg) did not significantly affect the total time that male mice (n = 610) spent on the Rota-Rod, F(3, 66) = 0.44, p > 0.05 (see Figure 4a). In a dose-dependent
manner, Abilify (0.1 – 20 mg/kg) significantly affected the total time that female mice (n = 6-10)
spent on the Rota-Rod, F(3, 64) = 13.27, p < 0.001 (see Figure 4b). Tukey’s post-hoc test
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verified that all three doses significantly impacted total time spent on the Rota-Rod in females, as
compared to their baseline times.
As dose increased, male mice’s (n = 6-10) coordination was significantly inhibited,
showing less moves at 20mg dose, F(3, 31) = 11.90, p < 0.001 (see Figure 5a). Tukey’s post-hoc
test showed the 20mg dose to inhibit coordination significantly compared to the 0.1mg/kg dose,
the 5mg/kg dose, and baseline. As dose increased, female mice’s (n = 6-10) coordination was
significantly inhibited, showing less moves at 20mg dose, F(3, 32) = 27.54, p < 0.001 (see
Figure 5b). Tukey’s post-hoc test showed the 20mg dose to inhibit coordination significantly
compared to the 0.1mg/kg dose, the 5mg/kg dose, and baseline.
As dose increased, male mice’s (n = 6-10) rest time significantly increased, F(3, 31) =
34.29, p < 0.001 (see Figure 6a). Tukey’s post-hoc test showed the 20mg/kg dose to significantly
increase rest time compared to the other doses and baseline, and the 5mg/kg dose significantly
increased rest time compared to baseline. As dose increased, female mice’s (n = 6-10) rest time
significantly increased, F(3, 32) = 68.67, p < 0.001 (see Figure 6b). Tukey’s post-hoc test
showed all doses to be significant compared to each other and to baseline.
As dose increased, male mice’s (n = 6-10) stereotypic movements significantly
decreased, F(3, 31) = 9.75, p < 0.001 (see Figure 7a). Tukey’s post-hoc test showed the 20mg/kg
dose to cause less stereotypy moves compared to the other doses, and 0.1mg/kg to cause
significantly more stereotypic movements compared to baseline. As dose decreased, female
mice’s (n = 6-10) stereotypic movements significantly increased, F(3, 32) = 14.17, p < 0.001
(see Figure 7b). Tukey’s post-hoc test showed the 0.1mg/kg to cause significantly more
stereotypic movements compared to the 5mg/kg dose, the 20mg/kg dose, and baseline.
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In a dose-dependent manner, Abilify significantly impacted the number of stereotypic
episodes in male mice (n = 6-10), F(3, 31) = 10.16, p < 0.001 (see Figure 8a). Tukey’s post-hoc
test showed that the 0.1mg/kg significantly increased stereotypy episodes compared to baseline,
and that the 20mg/kg dose significantly reduced stereotypy episodes compared to the other
doses. In a dose-dependent manner, Abilify significantly impacted the number of stereotypic
episodes in female mice (n = 6-10), F(3, 32) = 19.90, p < 0.001 (see Figure 8b). Tukey’s posthoc test showed that the 0.1mg/kg significantly increased stereotypy episodes compared to the
other doses and baseline, and that the 20mg/kg dose significantly reduced stereotypy episodes
compared to the other doses and baseline.
In a dose-dependent manner, Abilify significantly impacted time spent engaging in
stereotypy in male mice (n = 6-10), F(3, 31) = 9.24, p < 0.001 (see Figure 9a). Tukey’s post-hoc
test showed the 0.1mg/kg dose to significantly increase stereotypy time compared to baseline,
and the 20mg/kg dose to significantly decrease stereotypy time compared to the other doses. As
dose decreased, time spent engaging in stereotypy significantly increased in female mice (n = 610), F(3, 32) = 9.20, p < 0.001 (see Figure 9b). Tukey’s post-hoc test showed the 0.1mg/kg dose
to significantly increase stereotypy time compared to the other doses and baseline.
Discussion
Our hypothesis that Abilify would improve memory was not supported by our results.
The cognitive enhancement of atypical antipsychotics is attributed to antagonist activity at 5-HT6
and 5-HT7 receptors, and since aripiprazole works as an antagonist at 5-HT7 receptors, we
expected to see Abilify enhance cognition in our study. However, neither the males nor the
females showed cognitive improvement. The male mice committed the most errors at the
20mg/kg dose, the second most at the 0.1mg/kg dose, and the fewest at the 5mg/kg dose, while
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the exact opposite pattern was true for the female mice. Such contradictory results are difficult to
interpret. While both males and females spent more time in the maze at the highest dose, the
effect was significant only for the females, which might have something to do with the
involvement of prolactin in the females. Our findings regarding coordination showed that the
female mice’s coordination was more inhibited compared to the male mice, meaning that the
female mice perhaps took longer in the maze at the highest dose due to greater inhibited
coordination than the males, rather than any cognitive differences. While the results conflicted
with our hypothesis, we could see gender differences at doses showing that most errors were
committed by excessive time spent in maze. Again, this memory problem could be due to a
prolactin change in females that was not seen in males.
We hypothesized that the highest dose would inhibit coordination, which was mostly
supported by our findings. While the results were not significant for the male mice, all doses
produced shorter distances traveled in the Rota-Rod compared to baseline for the female mice.
Remarkably, even the lowest dose had a stronger impact on female mice than any of the doses
had on the male mice. Also, the lowest and highest dose produced less distance travelled than the
middle dose. The time spent by male mice on the Rota-Rod was not significant depending on
dose, and the results were quite consistent across the doses and baseline. All doses significantly
reduced time on the Rota-Rod compared to baselines for the female mice. The female mice
seemed to experience inhibited coordination at all doses, whereas the males experienced no
significant inhibition. Also, the middle dose was closest to the baselines for the females, once
again. The highest dose caused significantly fewer moves and thus showed inhibited
coordination among the male mice. The lowest and middle dose produced more moves than
baseline, without being significant. The highest dose caused significantly fewer moves in the
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female mice as well, indicating inhibited coordination. In males, the highest dose produced
significant effects across all conditions, while the middle dose also produced significantly more
rest time compared to baseline. All doses significantly increased rest time compared to baseline
in female mice, and the rest time also increased significantly in a dose-dependent manner.
We hypothesized that the lowest dose would increase stereotypy and that the highest dose
would inhibit stereotypy, which was generally supported by our findings. In male mice, the
highest dose produced significantly fewer stereotypic moves compared to the other doses, and
the lowest dose produced significantly more moves compared to baseline. In females, the lowest
dose produced significantly more stereotypic moves compared to the other doses and baseline,
while the highest dose produced less stereotypic moves in a non-significant manner, and the
middle dose was comparable to baseline. In male mice, the lowest dose produced significantly
more stereotypic episodes compared to the highest dose and baseline, and the highest dose
produced significantly more episodes compared to the middle dose. In females, the lowest dose
produced significantly more episodes compared to the other doses and baseline, and the highest
dose produced significantly fewer episodes compared to the other doses and baseline. In male
mice, there was a significant difference in stereotypy time between the highest and the lowest
dose, while the lowest dose produced significantly longer time than baseline, and the highest
dose produced significantly less time than the middle dose. In female mice, the lowest dose
produced significantly more stereotypy time compared to the other doses and baseline.
At moderate to high doses of Abilify, catalepsy or a modified form of catalepsy may arise
when individulas sustain their limbs in the same position for very long periods of time, which
may lead to significant health problems, such as formation of the blood clots. Also, since high
doses of Abilify is linked to slowing down of bodily functions a possible future study should
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include evaluating respiratory depression. Also, we did note gender differences among the male
and female mice, and these differences could be investigated by future studies.
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Figure 1a. Latency-to-goal in seconds for male mice in a cognitive maze at 0.1mg/kg, 5 mg/kg,
and 20mg/kg doses of Abilify.
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Figure 1b
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Figure 1b. Latency-to-goal in seconds for female mice in a cognitive maze at 0.1mg/kg, 5
mg/kg, and 20mg/kg doses of Abilify.
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Figure 2a
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Figure 2a. Number of errors made by male mice in a cognitive maze at 0.1mg/kg, 5 mg/kg, and
20mg/kg doses of Abilify.
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Figure 2b
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Figure 2b. Number of errors made by female mice in a cognitive maze at 0.1mg/kg, 5 mg/kg,
and 20mg/kg doses of Abilify.
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Figure 3a
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Figure 3a. Distance traveled in cm by male mice on the Rota-Rod at 0.1mg/kg, 5 mg/kg, and
20mg/kg doses of Abilify.
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Figure 3b
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Figure 3b. Distance traveled in cm by female mice on the Rota-Rod at 0.1mg/kg, 5 mg/kg, and
20mg/kg doses of Abilify.
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Figure 4a
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Figure 4a. Time in seconds spent by male mice on the Rota-Rod at 0.1mg/kg, 5 mg/kg, and
20mg/kg doses of Abilify.
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Figure 4b
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Figure 4b. Time in seconds spent by female mice on the Rota-Rod at 0.1mg/kg, 5 mg/kg, and
20mg/kg doses of Abilify.
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Figure 5a
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Figure 5a. Number of fixed moves made by male mice in the Tru-Scan at 0.1mg/kg, 5 mg/kg,
and 20mg/kg doses of Abilify.

36

CHARACTERIZING THE BEHAVIORAL EFFECTS OF ARIPIPRAZOLE

37

Figure 5b
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Figure 5b. Number of fixed moves made by female mice in the Tru-Scan at 0.1mg/kg, 5 mg/kg,
and 20mg/kg doses of Abilify.
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Figure 6a
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Figure 6a. Rest time in seconds spent by male mice in the Tru-Scan at 0.1mg/kg, 5 mg/kg, and
20mg/kg doses of Abilify.
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Figure 6b
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Figure 6b. Rest time in seconds spent by female mice in the Tru-Scan at 0.1mg/kg, 5 mg/kg, and
20mg/kg doses of Abilify.
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Figure 7a
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Figure 7a. Number of stereotypic moves made by male mice in the Tru-Scan at 0.1mg/kg, 5
mg/kg, and 20mg/kg doses of Abilify.
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Figure 7b
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Figure 7b. Number of stereotypic moves made by female mice in the Tru-Scan at 0.1mg/kg, 5
mg/kg, and 20mg/kg doses of Abilify.
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Figure 8a
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Figure 8a. Number of stereotypic episodes made by male mice in the Tru-Scan at 0.1mg/kg, 5
mg/kg, and 20mg/kg doses of Abilify.
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Figure 8b
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Figure 8b. Number of stereotypic episodes made by female mice in the Tru-Scan at 0.1mg/kg, 5
mg/kg, and 20mg/kg doses of Abilify.

CHARACTERIZING THE BEHAVIORAL EFFECTS OF ARIPIPRAZOLE

44

Figure 9a
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Figure 9a. Time in seconds spent by male mice making stereotypic movements in the Tru-Scan
at 0.1mg/kg, 5 mg/kg, and 20mg/kg doses of Abilify.
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Figure 9b
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Figure 9b. Time in seconds spent by female mice making stereotypic movements in the TruScan at 0.1mg/kg, 5 mg/kg, and 20mg/kg doses of Abilify.
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Table 1. Statistical analysis of Abilify’s effect on coordination in males.
Parameter
Table Analyzed
One-way analysis of variance
P value
P value summary
Are means signif. different? (P < 0.05)
Number of groups
F
R squared
Bartlett's test for equal variances
Bartlett's statistic (corrected)
P value
P value summary
Do the variances differ signif. (P < 0.05)
ANOVA Table
Treatment (between columns)
Residual (within columns)
Total
Tukey's Multiple Comparison Test
0.1 vs 5
0.1 vs 20
0.1 vs Baseline
5 vs 20
5 vs Baseline
20 vs Baseline

Rotorod Time Males

0.7192
ns
No
4
0.4484
0.01998

3.134
0.3715
ns
No
SS
36.44
1788
1824

df
3
66
69

MS
12.15
27.09

Mean Diff.
1.850
0.4500
1.000
-1.400
-0.8500
0.5500

q
1.590
0.3157
0.8592
0.9822
0.7304
0.3859

Significant? P < 0.05?
No
No
No
No
No
No

Summary
ns
ns
ns
ns
ns
ns

95% CI of diff
-2.493 to 6.193
-4.869 to 5.769
-3.343 to 5.343
-6.719 to 3.919
-5.193 to 3.493
-4.769 to 5.869
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Table 2. Statistical analysis of Abilify’s effect on coordination in females.
Parameter
Table Analyzed
One-way analysis of variance
P value
P value summary
Are means signif. different? (P < 0.05)
Number of groups
F
R squared
Bartlett's test for equal variances
Bartlett's statistic (corrected)
P value
P value summary
Do the variances differ signif. (P < 0.05)
ANOVA Table
Treatment (between columns)
Residual (within columns)
Total
Tukey's Multiple Comparison Test
0.1 vs 5
0.1 vs 20
0.1 vs Baseline
5 vs 20
5 vs Baseline
20 vs Baseline

Rotorod Time
Females

< 0.0001
***
Yes
4
13.27
0.3835

18.69
0.0003
***
Yes
SS
3175
5105
8280

df
3
64
67

MS
1058
79.76

Mean Diff.
-0.6500
6.300
-13.50
6.950
-12.85
-19.80

q
0.3255
2.385
6.760
2.631
6.435
7.495

Significant? P < 0.05?
No
No
Yes
No
Yes
Yes

Summary
ns
ns
***
ns
***
***

95% CI of diff
-8.106 to 6.806
-3.563 to 16.16
-20.96 to -6.044
-2.913 to 16.81
-20.31 to -5.394
-29.66 to -9.937
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Table 3. Statistical analysis of Abilify’s effect on endurance in males.
Parameter
Table Analyzed

Rotorod Distance
Males

One-way analysis of variance
P value
P value summary
Are means signif. different? (P < 0.05)
Number of groups
F
R squared

0.2994
ns
No
4
1.238
0.03266

Bartlett's test for equal variances
Bartlett's statistic (corrected)
P value
P value summary
Do the variances differ signif. (P < 0.05)

39.10
< 0.0001
***
Yes

ANOVA Table
Treatment (between columns)
Residual (within columns)
Total
Tukey's Multiple Comparison Test
0.1 vs 5
0.1 vs 20
0.1 vs Baseline
5 vs 20
5 vs Baseline
20 vs Baseline

SS
4260
126200
130400

df
3
110
113

MS
1420
1147

Mean Diff.
6.400
2.000
-8.734
-4.400
-15.13
-10.73

q
0.8451
0.2156
1.424
0.4744
2.467
1.318

Significant? P < 0.05?
No
No
No
No
No
No

Summary
ns
ns
ns
ns
ns
ns

95% CI of diff
-21.57 to 34.37
-32.26 to 36.26
-31.39 to 13.92
-38.66 to 29.86
-37.79 to 7.525
-40.81 to 19.34
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Table 4. Statistical analysis of Abilify’s effect on endurance in females.
Parameter
Table Analyzed

Rotorod Distance
Females

One-way analysis of variance
P value
P value summary
Are means signif. different? (P < 0.05)
Number of groups
F
R squared

< 0.0001
***
Yes
4
8.831
0.2030

Bartlett's test for equal variances
Bartlett's statistic (corrected)
P value
P value summary
Do the variances differ signif. (P < 0.05)

48.65
< 0.0001
***
Yes

ANOVA Table
Treatment (between columns)
Residual (within columns)
Total
Tukey's Multiple Comparison Test
0.1 vs 5
0.1 vs 20
0.1 vs Baseline Females
5 vs 20
5 vs Baseline Females
20 vs Baseline Females

SS
49540
194500
244000

df
3
104
107

MS
16510
1870

Mean Diff.
q Significant? P < 0.05? Summary
-2.950 0.3051
No
ns
13.13 1.026
No
ns
-41.48 5.254
Yes
**
16.08 1.257
No
ns
-38.53 4.881
Yes
**
-54.61 4.745
Yes
**

95% CI of diff
-38.72 to 32.82
-34.19 to 60.44
-70.69 to -12.28
-31.24 to 63.39
-67.74 to -9.330
-97.18 to -12.04
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Rota-Rod series 8 model
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